{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:00:11Z","timestamp":1778551211579,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":33,"publisher":"Springer New York","isbn-type":[{"value":"9781493933853","type":"print"},{"value":"9781493933877","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3387-7_14","type":"book-chapter","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:08:16Z","timestamp":1460632096000},"page":"269-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant"],"prefix":"10.1007","author":[{"given":"Clifton","family":"McPherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Chubet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Holtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Honda-Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","unstructured":"Nicholls J, Dong XP, Jiang G et al (2003) SARS: clinical virology and pathogenesis. Respirology 8 Suppl:S6\u2013S8","DOI":"10.1046\/j.1440-1843.2003.00517.x"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2003.09.011","volume":"29","author":"A Berger","year":"2004","unstructured":"Berger A, Drosten C, Doerr HW et al (2004) Severe acute respiratory syndrome (SARS)\u2014paradigm of an emerging viral infection. J Clin Virol 29:13\u201322","journal-title":"J Clin Virol"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1306742","volume":"369","author":"A Assiri","year":"2013","unstructured":"Assiri A, McGeer A, Perl TM et al (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369:407\u2013416","journal-title":"N Engl J Med"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.1085953","volume":"300","author":"MA Marra","year":"2003","unstructured":"Marra MA, Jones SJ, Astell CR et al (2003) The Genome sequence of the SARS-associated coronavirus. Science 300:1399\u20131404","journal-title":"Science"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1086\/522431","volume":"196","author":"ME Darnell","year":"2007","unstructured":"Darnell ME, Plant EP, Watanabe H et al (2007) Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis 196:1329\u20131338","journal-title":"J Infect Dis"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles M, Deming D, Long K et al (2011) A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85:12201\u201312215","journal-title":"J Virol"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1099\/vir.0.81579-0","volume":"87","author":"RH See","year":"2006","unstructured":"See RH, Zakhartchouk AN, Petric M et al (2006) Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87:641\u2013650","journal-title":"J Gen Virol"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","volume":"181","author":"F Yasui","year":"2008","unstructured":"Yasui F, Kai C, Kitabatake M et al (2008) Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 181:6337\u20136348","journal-title":"J Immunol"},{"key":"14_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng CT, Sbrana E, Iwata-Yoshikawa N et al (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7, e35421","journal-title":"PLoS One"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1128\/JVI.06791-11","volume":"86","author":"C Clay","year":"2012","unstructured":"Clay C, Donart N, Fomukong N et al (2012) Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol 86:4234\u20134244","journal-title":"J Virol"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/erv.09.43","volume":"8","author":"RL Roper","year":"2009","unstructured":"Roper RL, Rehm KE (2009) SARS vaccines: where are we? Expert Rev Vaccines 8:887\u2013898","journal-title":"Expert Rev Vaccines"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450\u2013454","journal-title":"Nature"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"15748","DOI":"10.1073\/pnas.0403812101","volume":"101","author":"SA Jeffers","year":"2004","unstructured":"Jeffers SA, Tusell SM, Gillim-Ross L et al (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101:15748\u201315753","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.4049\/jimmunol.173.6.4050","volume":"173","author":"Y He","year":"2004","unstructured":"He Y, Zhou Y, Wu H et al (2004) Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 173:4050\u20134057","journal-title":"J Immunol"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.4049\/jimmunol.174.8.4908","volume":"174","author":"Y He","year":"2005","unstructured":"He Y, Lu H, Siddiqui P et al (2005) Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174:4908\u20134915","journal-title":"J Immunol"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.1016\/j.vaccine.2007.06.047","volume":"25","author":"J Huang","year":"2007","unstructured":"Huang J, Cao Y, Du J et al (2007) Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 25:6981\u20136991","journal-title":"Vaccine"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1016\/j.vaccine.2006.01.059","volume":"24","author":"Z Zhou","year":"2006","unstructured":"Zhou Z, Post P, Chubet R et al (2006) A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24:3624\u20133631","journal-title":"Vaccine"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0264-410X(01)00301-2","volume":"20","author":"Peter J.M. Openshaw","year":"2001","unstructured":"Openshaw PJ, Culley FJ, Olszewska W (2001) Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20 Suppl 1:S27\u2013S31","journal-title":"Vaccine"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488\u2013496","journal-title":"Immunol Cell Biol"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/glycob\/cwt053","volume":"23","author":"PD Cooper","year":"2013","unstructured":"Cooper PD, Barclay TG, Ginic-Markovic M et al (2013) The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. Glycobiology 23:1164\u20131174","journal-title":"Glycobiology"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/glycob\/cwq201","volume":"21","author":"PD Cooper","year":"2011","unstructured":"Cooper PD, Petrovsky N (2011) Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 -> 1] poly(fructo-furanosyl) alpha-D-glucose polymers. Glycobiology 21:595\u2013606","journal-title":"Glycobiology"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","volume":"30","author":"Y Honda-Okubo","year":"2012","unstructured":"Honda-Okubo Y, Saade F, Petrovsky N (2012) Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30:5373\u20135381","journal-title":"Vaccine"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","volume":"91","author":"M Lobigs","year":"2010","unstructured":"Lobigs M, Pavy M, Hall RA et al (2010) An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 91:1407\u20131417","journal-title":"J Gen Virol"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1128\/CVI.00019-14","volume":"21","author":"B Feinen","year":"2014","unstructured":"Feinen B, Petrovsky N, Verma A et al (2014) Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin Vaccine Immunol 21:580\u2013586","journal-title":"Clin Vaccine Immunol"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1016\/j.vaccine.2014.06.057","volume":"32","author":"Y Honda-Okubo","year":"2014","unstructured":"Honda-Okubo Y, Kolpe A, Li L et al (2014) A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. Vaccine 32:4651\u20134659","journal-title":"Vaccine"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/JVI.03144-12","volume":"87","author":"M Larena","year":"2013","unstructured":"Larena M, Prow NA, Hall RA et al (2013) JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+ T cells and pre-exposure neutralizing antibody. J Virol 87:4395\u20134402","journal-title":"J Virol"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","volume":"29","author":"RC Layton","year":"2011","unstructured":"Layton RC, Petrovsky N, Gigliotti AP et al (2011) Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29:6242\u20136251","journal-title":"Vaccine"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"10324","DOI":"10.1128\/JVI.00480-13","volume":"87","author":"N Petrovsky","year":"2013","unstructured":"Petrovsky N, Larena M, Siddharthan V et al (2013) An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 87:10324\u201310333","journal-title":"J Virol"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","volume":"31","author":"F Saade","year":"2013","unstructured":"Saade F, Honda-Okubo Y, Trec S et al (2013) A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31:1999\u20132007","journal-title":"Vaccine"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1099\/vir.0.023242-0","volume":"92","author":"AD Cristillo","year":"2011","unstructured":"Cristillo AD, Ferrari MG, Hudacik L et al (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 92:128\u2013140","journal-title":"J Gen Virol"},{"issue":"48","key":"14_CR31","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","volume":"32","author":"D Gordon","year":"2014","unstructured":"Gordon D, Kelley P, Heinzel S et al (2014) Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine 32(48):6469\u20136477","journal-title":"Vaccine"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","volume":"30","author":"DL Gordon","year":"2012","unstructured":"Gordon DL, Sajkov D, Woodman RJ et al (2012) Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30:5407\u20135416","journal-title":"Vaccine"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo Y, Barnard D, Ong CH et al (2015) Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 89:2995\u20133007","journal-title":"J Virol"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3387-7_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T19:41:09Z","timestamp":1584474069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3387-7_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933853","9781493933877"],"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3387-7_14","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"14 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}